Updates to Medicare Advantage and the Part D Prescription Drug program will improve programs for health plans that provide care for vulnerable enrollees.
Updates to Medicare Advantage and the Part D Prescription Drug program will improve programs for health plans that provide care for vulnerable enrollees. The finalized payment and policy changes for 2017 also seek to provide table payments to plans.
The final updates have incorporated feedback received during the public comment period after the policies were first proposed in February.
“We continue to strengthen Medicare Advantage and Medicare Part D, in particular for enrollees who need additional investments in their health…” Acting Administrator Andy Slavitt said in a statement. “With these polices, we will continue to see improvements in growth, affordability, benefits, and quality for millions of seniors and people living with disabilities.”
These new updates will are expected to improve the accuracy of payments to MA plans, including a new methodology that should better reflect the cost of care, and the socioeconomic and disability status of the enrollee, in addition to increasing stability for the program within Puerto Rico.
The anticipated revenue change is approximately 0.85%, not counting the typical 2.2% added in from the growth in coding acuity. This is somewhat smaller than the first estimate in the February Advance Notice due to technical updates in the risk adjustment normalization factor.
CMS policies are also being finalized for discouraging opioid overutilization.
LLMs Show Promise, But Challenges Remain in Improving Inefficient Clinical Trial Screening
July 31st 2025Large language models (LLMs) such as GPT-3.5 and GPT-4 may offer a solution to the costly and inefficient process of manual clinical trial screening, which is often hindered by the inability of structured electronic health record data to capture all necessary criteria.
Read More
Trends in Insulin Out-of-Pocket Costs and Use Disparities, 2008-2021
July 31st 2025Given trends in cost and use, insulin out-of-pocket cost reduction policies would be more efficient if they targeted members in high-deductible health plans with savings options and low-income patients.
Read More
The Legal Architecture of Psychedelic Therapy: Risks, Responsibilities, and Reimbursement Realities
July 30th 2025Key legal, ethical, and compliance considerations for managed care professionals navigating the evolving landscape of psychedelic-assisted therapy include regulatory risks, data privacy challenges, reimbursement limitations, and the need for culturally informed care models.
Read More